<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650818</url>
  </required_header>
  <id_info>
    <org_study_id>CEC641</org_study_id>
    <nct_id>NCT01650818</nct_id>
  </id_info>
  <brief_title>Aerobic Exercise Training in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>ENDURANCE</acronym>
  <official_title>Exercise traiNing in Amyotrophic Lateral Sclerosis: a ranDomized Trial Comparing Home-based Aerobic endUrance tRAiNing vs. Usual physiCal Therapy intErvention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Salvatore Maugeri</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and the effects of moderate-intensity
      aerobic endurance training to those of an usual physical therapy intervention on exercise
      capacity and quality of life in patients with amyotrophic lateral sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scarce evidence is available regarding aerobic exercise training of patients with ALS. Some
      studies using transgenic mouse models of familial ALS have shown markedly slowed disease
      progression, improved functional capacity, and extension of survival in animals undergoing
      aerobic exercise training. In humans, only one non-randomized study has shown that
      moderate-intensity aerobic exercise training was of little beneficial effect in a small group
      of patients with Kennedy disease, a rare X-linked progressive neuromuscular disease involving
      lower motorneurons, presenting a pathophysiological picture quite different from that of ALS.
      To the best of our knowledge, the safety and the effects of aerobic exercise training on
      functional capacity and quality of life of patients with ALS have not been systematically
      evaluated as yet in a randomized, controlled trial with an adequate sample size.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in peak oxygen consumption (peak VO2)</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on peak VO2, as assessed by cardiopulmonary exercise testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aerobic training safety and tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate aerobic training safety and tolerability in terms of adverse events incidence and adherence to training program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on quality of life, as assessed by McGill questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on the ALSFRS-R score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lower limbs muscle strength</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on isometric muscle strength of lower limbs, as assessed by isometric dynamometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in upper and lower motor neurons function at the upper and lower limbs level</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on upper and lower motor neurons function at the upper and lower limbs level, as determined by compound muscle action potential and neurophysiological index and motor evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ventilatory function</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on ventilatory function, as assessed by spirometry and measurement of maximal inspiratory and expiratory pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in circulating inflammatory markers, growth factors and descriptors of skeletal muscle damage</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the effects of aerobic training on circulating inflammatory markers and growth factors (CRP, TNF-alfa, IL-6, Angiogenin, Angiopoietin 1 and 2, Thrombospondin, VEGF, BDNF, IGF-1) and markers of skeletal muscle damage (CPK)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Aerobic exercise training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard physical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic exercise training</intervention_name>
    <description>Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month</description>
    <arm_group_label>Aerobic exercise training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard physical therapy (Stretching/Range-of-motion)</intervention_name>
    <description>Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month</description>
    <arm_group_label>Standard physical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of definite ALS, probable ALS, or probable-laboratory supported ALS
             according to the El Escorial criteria or diagnosis of progressive muscular atrophy.

          -  Ability to perform a baseline symptom-limited cardiopulmonary exercise test with
             attainment of peak power and respiratory exchange ratio of &gt;= 50 W and &gt;= 1.00,
             respectively.

          -  Time since symptoms onset &lt;= 18 months.

          -  Forced vital capacity &gt;= 70% of predicted.

          -  Informed written consent.

        Exclusion Criteria:

          -  Coexisting neurological disease.

          -  Coexisting extra-neurological disease significantly affecting exercise capacity.

          -  Coexisting malignancy.

          -  Ongoing/planned pregnancy.

          -  Involvement in formal endurance and/or strength training program.

          -  Enrolment in any other clinical trial.

          -  Cognitive impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Mezzani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Pisano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrizio Pisano, MD</last_name>
    <phone>+39-0322-884723</phone>
    <email>fabrizio.pisano@fsm.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno</name>
      <address>
        <city>Veruno</city>
        <zip>28010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Mezzani, MD, FESC</last_name>
      <phone>3403119299</phone>
      <email>alessandro.mezzani@fsm.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Mezzani, MD, FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mezzani A, Pisano F, Cavalli A, Tommasi MA, Corr√† U, Colombo S, Grassi B, Marzorati M, Porcelli S, Morandi L, Giannuzzi P. Reduced exercise capacity in early-stage amyotrophic lateral sclerosis: Role of skeletal muscle. Amyotroph Lateral Scler. 2012 Jan;13(1):87-94. doi: 10.3109/17482968.2011.601463. Epub 2011 Aug 11.</citation>
    <PMID>21830991</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>September 8, 2013</last_update_submitted>
  <last_update_submitted_qc>September 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Salvatore Maugeri</investigator_affiliation>
    <investigator_full_name>Alessandro Mezzani</investigator_full_name>
    <investigator_title>MD, FESC</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Aerobic training</keyword>
  <keyword>Peak oxygen consumption</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

